Incremental costs effectiveness ratios of the DNA-based methods compared with each other cholesterol method for screening and identification of FH
| Strategy | Cost | Effects (QALY) | Incremental cost | Incremental QALY | ICER (£/QALY) |
| Cholesterol | £44 576 | 10.89 | |||
| DNA | £50 918 | 24.12 | £6341 | 13.23 | £479 |
| DNA+CholM-ve DFH | £52 670 | 24.28 | – | – | ED* |
| DNA+CholM-ve DF+PFH | £54 799 | 25.18 | £3881 | 1.06 | £3666 |
↵* Ruled out by extended dominance (ED).
CholM-ve, cascade testing using LDL-C in relatives of mutation-negative index cases; FH, familial hypercholesterolaemia; ICER, cost-effectiveness ratios; QALY, quality-adjusted life-year.